How Much Does Peptide Therapy Cost in 2026? Prices by Compound, Clinic vs Telehealth, Insurance

Key takeaways

• In October 2026, most telehealth peptide programs cost $150 to $450 a month with medication included. GLP-1 therapy sits at the top of that range; sermorelin, NAD+ and PT-141 in the lower half; testosterone below it.
• Brand GLP-1 pens are no longer four-figure drugs for cash buyers: Wegovy is $349 a month through NovoCare ($199 for the first two fills for new patients in 2026), Zepbound is $299 to $449 by dose through LillyDirect, and both are on the federal TrumpRx site.
• Compounded semaglutide and tirzepatide are cheaper (about $150 to $350 a month) but are not FDA-approved, can only be legally prepared in limited circumstances since the shortages ended, and were the subject of 55 FDA warning letters to telehealth companies in 2026.
• The medication is often less than half the bill. First-month costs include a consultation ($0 to $200), labs ($100 to $400) and sometimes a membership fee.
• Compounded peptides are cash-pay. Brand GLP-1s may be covered by commercial insurance, and Medicare coverage for obesity is being introduced under a November 2025 agreement at a $50 copay.

What a monthly price actually includes

"$199 a month" can mean five different things. Before comparing two quotes, break each one into its parts.

A fair comparison is the total for the first three months, not the first month.

Prices by therapy, October 2026

Sources for each row are listed at the end of the page. Three patterns are worth noticing. The brand GLP-1 prices have dropped by two-thirds since early 2025, which has squeezed the price gap with compounded versions to a few hundred dollars a year at the lower doses. The cheapest compounded prices are almost always tied to a long commitment and the lowest dose. And the "wellness" peptides (sermorelin, NAD+, PT-141) cost about the same as each other, roughly $150 to $350, because the clinician and pharmacy costs dominate and the ingredients are cheap.

Brand versus compounded GLP-1s: the real gap

In March 2025 Novo Nordisk launched NovoCare Pharmacy with Wegovy at $499 a month for cash patients, then cut it to $349 in November 2025 when the two manufacturers reached a pricing agreement with the federal government. Lilly's LillyDirect program sells Zepbound vials at $299 to $449 depending on dose, with Walmart pickup added in late 2025. The federal TrumpRx site, live since early 2026, lists the same products at the same or lower prices and does not write prescriptions; you still need one from your own clinician.

Compounded semaglutide at $150 to $250 and compounded tirzepatide at $180 to $300 are therefore cheaper, but less dramatically than in 2024, and they come with conditions. FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage in February 2025, which ended the period in which pharmacies could compound copies in volume. In 2026 FDA sent warning letters to 30 telehealth companies in March and 25 more in June over marketing of compounded GLP-1s that implied they were equivalent to, or approved like, the brand products. A compounded GLP-1 can still be legal for an individual patient with a documented clinical need the approved product cannot meet; a website offering it to everyone at a discount is a different thing. Our semaglutide versus tirzepatide guide covers the clinical differences.

Clinic versus telehealth

Telehealth is cheaper in almost every case because the clinician time is shorter and the pharmacy relationship is direct. A local clinic earns its price when you need a physical examination, in-office IV therapy or a hands-on injection teaching session, or when the compound is one that telehealth programs do not offer.

Insurance, Medicare, HSA and FSA

Compounded peptides: cash. Insurers do not cover compounded sermorelin, NAD+, PT-141 or compounded GLP-1s except in rare case-by-case appeals.

Brand GLP-1s: coverage depends on the diagnosis and the plan. Type 2 diabetes (Ozempic, Mounjaro) is widely covered; obesity (Wegovy, Zepbound) is covered by some commercial plans, usually with prior authorization and a BMI threshold. Novo Nordisk states that most commercially insured Wegovy patients pay $25 or less a month with its savings card; the cash programs exclude anyone with Medicare, Medicaid, TRICARE or VA coverage.

Medicare: federal law has long prohibited Medicare Part D from covering drugs for weight loss. The November 6, 2025 agreement announced a $245 Medicare price for Ozempic, Wegovy, Mounjaro and Zepbound, Medicare coverage of Wegovy and Zepbound for patients with obesity and related conditions, and a $50 monthly copay; the fact sheet gave no start date, so check the current status with your plan.

HSA and FSA: prescribed medications and the clinician visits to obtain them are qualified medical expenses under IRS Publication 502, so compounded prescriptions generally qualify even though insurance does not cover them. Supplements, cosmetic peptides and anything bought without a prescription do not. Keep the prescription and an itemized receipt showing the drug name.

What makes a quote cheap or expensive

• Commitment. The lowest advertised prices are for 6- or 12-month plans paid upfront. Month-to-month is $50 to $150 more.
• Dose escalation pricing. GLP-1 programs often price by dose. A $99 starting month can become $280 to $385 at the 10 to 15 mg tirzepatide doses.
• Membership fees. $40 to $100 a month on top of the medication at some clinics.
• Labs. Mandatory for hormone and testosterone programs; a hidden $150 to $400 at the start.
• 503A versus 503B. Outsourcing-facility (503B) product, made under FDA-inspected conditions in batches, costs more than a 503A pharmacy filling individual prescriptions.
• Pen versus vial. Brand pens and KwikPens cost more to make than a vial and syringe.
• Clinician time. A program with a physician on video every month costs more than one with an initial intake and asynchronous messaging; whether that is worth it depends on the compound and on you.

Red flags on a price list

• "Research grade" or "RUO" pricing at a fraction of pharmacy cost. The product has no label, no prescription and no legal path to human use. FDA's August 2026 warning letters to five peptide vendors treated dosing calculators, injection instructions and bundled bacteriostatic water as proof that research-labeled vials were being sold as drugs.
• No pharmacy named. A legitimate program will tell you which licensed pharmacy fills the prescription and in which state.
• No clinician, or a "consultation" that is a form. A prescription requires a licensed prescriber and a legitimate evaluation.
• Peptides that cannot be legally compounded sold as "fully legal." BPC-157, TB-500 and similar compounds are not on FDA's permitted list as of October 2026, whatever an advisory committee recommended in July. See the legal tracker.
• "Same as Wegovy" or "FDA-approved ingredients" claims for compounded GLP-1s. This is the language FDA's 2026 warning letters targeted.
• Prices that assume a dose far below the studied dose. A $120 sermorelin plan at 100 mcg a night is not the same product as the trials' 1 to 2 mg.

Seven questions before you pay

1. What is the total for the first three months, including labs, visits, shipping and any membership?
2. What happens to the price at the next dose?
3. Which pharmacy fills it, and is it a 503A pharmacy or a 503B outsourcing facility?
4. Is this compound legally compoundable right now, or is it a research vial?
5. Is the clinician licensed in my state, and will I see the same one?
6. What is the cancellation policy, and is unused medication refundable?
7. Will I get a labeled vial with the concentration and a beyond-use date?

Bottom line

Peptide therapy in 2026 costs $150 to $450 a month for most people, and the biggest variable is no longer the drug but the model: brand or compounded, clinic or telehealth, month-to-month or committed. Brand GLP-1 prices have fallen far enough that the compounded discount is modest at low doses, and the legal and quality differences are not modest at all. Price the first three months, name the pharmacy, and treat any "research" price as a different product.

Frequently asked questions

+−How much does peptide therapy cost per month?

In October 2026, most telehealth peptide programs cost between about $150 and $450 a month including the medication, with the GLP-1 drugs at the top of that range and single peptides such as sermorelin or NAD+ in the lower half. Brand GLP-1 pens bought for cash cost $299 to $449 a month through the manufacturer programs. Labs, a first consultation and membership fees can add $100 to $400 in the first month.

+−Does insurance cover peptide therapy?

Compounded peptides are almost never covered; you pay cash. Brand GLP-1 drugs are covered by some commercial plans for obesity and by most for type 2 diabetes, with wide variation in prior-authorization rules. Medicare has historically been barred from covering drugs for weight loss; a November 2025 agreement between the federal government and the two manufacturers set a $245 Medicare price and a $50 copay for patients with obesity and related conditions, with implementation details still being rolled out.

+−Can I use my HSA or FSA for peptides?

Usually yes for a prescribed medication and the clinician visit, because prescribed drugs and medical care are qualified medical expenses. Supplements, cosmetic peptides and anything bought without a prescription are not. Keep the prescription and the itemized receipt.

+−Why is compounded semaglutide cheaper than Wegovy?

A compounding pharmacy buys semaglutide as a bulk ingredient and fills it into vials; there is no research, approval or marketing cost built in, and no pen device. The trade-off is that the product is not FDA-approved, is not tested by FDA for potency or purity, and since the shortage ended in February 2025 can only be legally prepared in limited circumstances. The brand price has also fallen: $349 a month for Wegovy through NovoCare, and $199 for the first two months for new patients in 2026.

+−How much does sermorelin cost?

Roughly $150 to $400 a month through telehealth in 2026, usually including the clinician visits, with a few programs advertising injections from about $120 and lozenges from about $99. Baseline labs, if required, add $150 to $400 in the first month. Prices depend heavily on the dose, because sermorelin is dosed daily and a 15 mg vial lasts a different number of days at 200 mcg than at 500 mcg.

+−Why are research peptides so much cheaper?

Because you are paying for an unlabeled vial, not a medication. A research vial has no prescription, no clinician, no pharmacy, no verified content and no legal path to human use; FDA treats products sold that way with dosing instructions as unapproved drugs and sent warning letters to five vendors in August 2026. The price is not comparable, and neither is the risk.

+−Are the cheapest telehealth prices real?

The headline price is usually real for the lowest dose on the longest commitment, paid upfront. Read what happens at month two (dose escalation pricing), whether there is a membership or shipping fee, whether labs are mandatory, and whether the price is locked. A $99 starting price that becomes $300 at the maintenance dose is common.

Sources

1. NewsNovo Nordisk. Novo Nordisk introduces NovoCare Pharmacy, lowering cost of all doses of FDA-approved Wegovy to $499 per month for cash-paying patients. Press release, March 2025. (2025)
2. NewsManaged Healthcare Executive. Novo Nordisk lowers Wegovy price for cash-paying patients (to $349 per month). November 2025. (2025)
3. RegulatoryThe White House. Fact sheet: major developments in bringing most-favored-nation pricing to American patients (GLP-1 agreements with Novo Nordisk and Eli Lilly; TrumpRx prices; Medicare and Medicaid terms). November 6, 2025. (2025)
4. NewsWalmart. LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound. October 29, 2025. (2025)
5. NewsCBS News. TrumpRx: the drugs available on the administration's discounted drug site. 2026. (2026)
6. RegulatoryFDA. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. Press announcement, March 2026. (2026)
7. NewsTelehealth.org. FDA sends new round of warning letters (25 companies) over compounded GLP-1 marketing claims. June 2026. (2026)
8. NewsArentFox Schiff. RUO-ined: five peptide vendors learn that research use only is not a legal strategy (FDA warning letters of August 24, 2026). September 18, 2026. (2026)
9. SourceForbes Health. Cheapest online tirzepatide providers (2026). (2026)
10. SourceTelehealth Ledger. Compounded tirzepatide prices, September 2026 (price tracker). (2026)
11. SourceTesting.com. Compounded semaglutide cost: what you will pay monthly (August 2026). (2026)
12. SourceHealingMaps. How much does sermorelin cost? The 2026 pricing guide (affiliate site; prices as listed by providers). (2026)
13. SourceHealingMaps. How much does NAD+ therapy cost in 2026? IV drips vs injections vs nasal spray (affiliate site). (2026)
14. SourceMedFinder. Tesamorelin: brand and compounded pricing (2026). (2026)
15. SourceCompounding Finder. PT-141 (bremelanotide): compounded pricing directory.
16. SourceISSM. How does the cost of testosterone therapy from a telemedicine platform compare to that from a tertiary center? (summary of a 2022 cost comparison).
17. RegulatoryIRS. Publication 502, Medical and Dental Expenses (what counts as a qualified medical expense for HSA and FSA purposes).